Extended Data Fig. 1: Supplementary progression-free survival in patients in the double-blind intention-to-treat population grouped according to tumor PD-L1 expression level. | Nature Cancer

Extended Data Fig. 1: Supplementary progression-free survival in patients in the double-blind intention-to-treat population grouped according to tumor PD-L1 expression level.

From: Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC

Extended Data Fig. 1

a, All patients. Sugemalimab group, N = 320 patients; Placebo group, N = 159 patients. b, Patients with PD-L1 ≥ 1%. Sugemalimab group, N = 196 patients; Placebo group, N = 96 patients.c, Patients with PD-L1 < 1%. Sugemalimab group, N = 124 patients; Placebo group, N = 63 patients. d, Patients with PD-L1 1–49%. Sugemalimab group, N = 92 patients; Placebo group, N = 48 patients.e, Patients with PD-L1 ≥ 50%. Sugemalimab group, N = 104 patients; Placebo group, N = 47 patients. CI, confidence interval; HR, hazard ratio; PD-L1, programmed death ligand 1.

Source data

Back to article page